83 results about "Meglumine" patented technology

The invention relates to the technical field of medicines, in particular to a compound amlodipine atorvastatin calcium tablet and a production mixing device. The compound amlodipine atorvastatin calcium tablet is a core-coated tablet and comprises an inner-layer tablet core containing atorvastatin calcium and an outer-layer tablet layer containing amlodipine besylate, the inner-layer tablet core further comprises meglumine and sodium lauryl sulfate, the mass ratio of meglumine to sodium lauryl sulfate is (0.5-5): 1, the mass ratio of meglumine to sodium lauryl sulfate is (0.5-5): 1, and the mass ratio of meglumine to sodium lauryl sulfate is (0.5-5): 1. And the mass of the meglumine accounts for 1-3% of the total mass of the inner-layer tablet core. The amlodipine and atorvastatin calcium are prepared into the coated tablet, so that two active ingredients in the same tablet are effectively isolated, and the compatibility of the atorvastatin calcium and the amlodipine besylate is remarkably improved; meanwhile, the inner layer and the outer layer of the core-coated sheet are separately granulated before tabletting, so that the problem that the mixing uniformity of total mixed particles is relatively poor when conventional tablets are prepared is effectively solved.

The invention relates to the field of medicines, and provides a tevirimat composition as well as a preparation method and application thereof. The composition contains tevirimat serving as an active component, cyclodextrin serving as an inclusion agent, meglumine serving as a solubilizer and an alkaline additive in a weight ratio of 1: (15-30): (0.05-0.2): (0.1-0.2). Wherein the solubility of the active ingredient tevirimat can be greatly improved through the matching and combined use of the three auxiliary materials including the inclusion agent, the solubilizer and the alkaline additive. Compared with the prior art, the dosage of each auxiliary material in the composition can meet the specified limit in related laws and regulations, the allergy risk, the hemolysis risk and the stimulation risk are low, and the preparation safety is better. The composition provided by the invention is simple and feasible in preparation method, more stable in preparation finished product quality and more convenient to apply. The composition can be used for treating or preventing virus infection and related diseases caused by orthopoxvirus.

The invention belongs to the technical field of medicines, and particularly relates to a flavonoid compound-meglumine co-amorphous substance and a preparation method thereof. The flavonoid compounds comprise baicalein, hesperetin, naringenin, kaempferol, quercetin, isoliquiritigenin and the like, and the co-amorphous substance consists of a single flavonoid compound and meglumine and is prepared by adopting a melting shock cooling method or a rotary evaporation method. The miscibility of the flavonoid compounds and the meglumine is screened through Hansen solubility. The crystal diffraction characteristics, thermodynamic properties and intermolecular interaction of the co-amorphous substance are measured through PXRD, DSC and FTIR, and it is shown that the six flavonoid compounds and meglumine successfully form a co-amorphous system. The solubility and the dissolution rate of the six flavonoid compound-meglumine co-amorphous substance are obviously superior to those of flavonoid bulk drugs, and the physical stability of the formed co-amorphous substance is obviously superior to that of a single amorphous drug, so that the co-amorphous substance shows good patent medicine performance.

The invention belongs to the technical field of contact lenses, and provides a contact lens ink and a preparation method thereof, the product comprises the following preparation raw materials by mass: 30-40 parts of a hydrophilic monomer, 10-20 parts of an organosilicon monomer, 10-15 parts of a functional monomer, 5-15 parts of a solvent, 1-5 parts of an auxiliary agent, 1-2 parts of a chain transfer agent, 0.5-1 part of a cross-linking agent, 0.5-0.8 part of an initiator, 1-5 parts of a pigment, and 1-1.5 parts of triethylene diamine. The organic silicon monomer enables the contact lens to have a double-channel structure of a silicon channel and a water channel, and oxygen in the air can penetrate through the lens to be in contact with the cornea, so that the oxygen deficit condition of eyes wearing the contact lens is improved. Meanwhile, the added auxiliaries are meglumine and allyloxy hydroxypropyl sodium sulfonate, and hydroxyl and sulfonic acid groups have hydrophilicity, so that the stability of the ink is improved, the contact angle of the surface of a lens can be obviously reduced, the surface wetting degree is increased, and the problem of difficult wetting is solved.

The invention discloses a rivaroxaban tablet. A tablet core is prepared from the following components in parts by weight: 10 parts of rivaroxaban, 15-25 parts of meglumine, 50-80 parts of a filling agent, 20-40 parts of a disintegrating agent and 0.5-1.5 parts of a lubricating agent; wherein the particle size D90 of the rivaroxaban is 50-100 [mu] m, and the invention discloses a preparation method of the rivaroxaban tablet, and the meglumine and the rivaroxaban are adopted to form a stable clathrate compound to prepare the preparation, so that the dissolution rate and the stability of the rivaroxaban tablet can be improved.

The invention discloses a water-phase synthesis method and application of a hierarchical pore metal organic framework material ZIF-8, and the specific preparation process is as follows: dissolving zinc nitrate hexahydrate in deionized water, stirring at 20-40 DEG C for 5-10 min, then adding a surfactant as a soft template until the surfactant is completely dissolved to obtain a solution A; dimethylimidazole is dissolved in deionized water, and a solution B is obtained; and uniformly mixing the solution A and the solution B, reacting at 20-40 DEG C for 2-6 hours, eluting and drying to obtain the hierarchical pore metal organic framework material ZIF-8. The hierarchical pore metal organic framework material prepared by the invention has strong capability of simultaneously adsorbing target molecules of diclofenac sodium, flunixin meglumine and meloxicam in an aqueous solution and high adsorption capacity, and can be used for adsorbing and removing the target molecules of diclofenac sodium, flunixin meglumine and meloxicam in an actual environmental sample.

The invention relates to the field of agricultural bactericides, in particular to a suspending agent containing fenaminstrobin and validamycin A and application of the suspending agent. The bactericidal composition comprises a suspending agent containing fenaminstrobin and validamycin A, an active component, a stabilizer, an auxiliary agent and water, the active component accounts for 1-70% of the mass of the preparation, and the stabilizer accounts for 0.1-10% of the mass of the preparation; wherein the active ingredients are fenaminstrobin and validamycin A, and the stabilizer is meglumine (N-methyl-D-glucosamine). The suspending agent prepared by the technical scheme of the invention effectively inhibits the increase of the particle size of a sample in the thermal storage process of a preparation, effectively improves the suspension rate of fenaminstrobin after the thermal storage of the preparation, improves the utilization rate of a pesticide, and ensures the normal exertion of the efficacy of the pesticide at the same time. Meanwhile, the quality of the active components of the stabilizer-containing bactericide is stable within the shelf life, the addition of the stabilizer does not cause the decomposition of the active components, and the preparation does not have obvious physical or chemical change.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an ambroxol hydrochloride-containing oral liquid and application thereof, and the ambroxol hydrochloride oral liquid is composed of ambroxol hydrochloride, ligustrazine, meglumine, dextran 40, xylitol, carboxymethylcellulose, L-tryptophan, stevioside and purified water. The ligustrazine and the ambroxol hydrochloride play a synergistic effect, and the meglumine and the dextran 40 are combined for use, so that the stability of the ambroxol hydrochloride is improved. Accelerated experiments show that the ambroxol hydrochloride is stable in property and suitable for further industrial mass production.

The invention discloses a pharmaceutical composition for treating diabetes and a preparation method thereof.The pharmaceutical composition comprises a tablet core and a coating layer, the tablet core comprises metformin hydrochloride, linagliptin, an adhesive, a stabilizer, a diluent, a flow aid and a lubricant, the stabilizer is composed of sodium hydroxide and meglumine, and the diluent is composed of sodium hydroxide and meglumine. The pharmaceutical composition for treating diabetes mellitus has good dissolution and stability.

The invention relates to the technical field of medicines, and provides a nalmefene hydrochloride injection and a preparation method thereof, every 1000 injections comprise the following components in parts by weight: 2.0 g of nalmefene hydrochloride based on nalmefene, 18g of osmotic pressure regulator, 0.05-0.1 g of meglumine, and the balance of water for injection to 2000mL. The preparation method comprises the following steps: S1, adding the osmotic pressure regulator and the meglumine in a prescription dosage into the water for injection which accounts for 90% of the total amount of the prescription dosage, stirring until the osmotic pressure regulator and the meglumine are dissolved, and regulating the pH value to 3.5-4.0 through a hydrochloric acid solution; s2, adding a prescription amount of nalmefene hydrochloride into the solution in the step S1, stirring until the nalmefene hydrochloride is dissolved, and adjusting the pH value to 3.5-3.8; and S3, adding water for injection to the total amount, uniformly stirring, filtering, canning into an ampoule bottle, sterilizing, carrying out lamp detection for leakage detection, and packaging. By adding a small amount of meglumine, the amount of the dinalmefene impurity generated by long-term placement and oxidation of the nalmefene hydrochloride injection can be reduced, adverse reactions possibly caused by a large amount of meglumine are reduced, the content of the dinalmefene impurity is maintained at a low level, and the use safety of the injection is improved.

This invention relates to an isosorbide dinitrate pharmaceutical composition injection and its preparation method. In addition to isosorbide dinitrate, the injection formulation also contains meglumine and glutathione. The preferred specifications are 5ml:5mg and 10ml:10mg. The isosorbide dinitrate injection prepared according to the formulation and process of this invention has the characteristics of high excipient safety, simple process, extremely high quality stability and good safety, which is significantly better than the prior art.

A composition for carbon dioxide (CO2) capture includes 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, meglumine, or combinations thereof. A process of CO2 capture includes mixing a CO2-containing gas with the composition. A system includes a component for receiving a gas and the composition, which absorbs CO2 from the gas. A further composition includes a first amine solvent selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, and meglumine and a second amine solvent independently selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, meglumine, ethyl diethanolamine, dimethylethanolamine, piperidine, 2-amino-2-methyl-1-propanol, and monoethanolamine. A further process includes reacting CO2 with an amine selected from 2-aminocyclohexanol, cis-1,2-diaminocyclohexane, and meglumine.

This invention discloses a meglumine-luteolin complex, its preparation method, and its applications, belonging to the interdisciplinary field of microbiome and drug delivery. Using luteolin as the main material, this invention employs a dual inclusion technique with hydroxypropyl-β-cyclodextrin and meglumine to synergistically prepare a meglumine-luteolin complex with colon-targeted delivery capabilities. This invention significantly improves the delivery efficiency and drug loading of luteolin in the colon through the dual inclusion technique. The preparation process is simple, and it exhibits excellent hypoglycemic effects and colon-targeted release characteristics in the treatment of diabetes and its complications.

The invention discloses a silybin meglumine oral liquid and a preparation method thereof. The method comprises the following steps: preparing silybin meglumine powder, a sweetening agent, an acidulant and purified water as raw materials; under the conditions that the stirring speed is 250 rpm and the water temperature is 25-30 DEG C, silybin meglumine powder is slowly scattered into the purified water to be stirred for 45 minutes until the silybin meglumine powder is completely dissolved; adding a sweetening agent and an acidulant, continuously stirring for 10 minutes, and then filtering through a 0.22 mu m microfiltration membrane to obtain a sterile and transparent solution; and subpackaging the solution into sterile oral liquid bottles, and sealing and packaging. The silybin meglumine oral liquid prepared by the method has the advantages of high dissolution efficiency, optimized taste, sterility, safety, stable quality and the like, is suitable for industrial large-scale production, and can remarkably improve the medication compliance of patients. The method is simple in process, easy to operate and low in cost, and has wide popularization and application values.

The present invention relates to a method for producing gadoteric acid meglumine using high-purity tetraracetam (DOTA). This method does not require the use of organic solvents and optimizes synthesis process conditions. The synthesis process for producing gadoteric acid meglumine using tetraracetam includes at least one electrodialysis purification step. This step can produce tetraracetam and gadoteric acid meglumine with minimal impurity content.

The invention discloses a preparation method of a silybin meglumine tablet, which comprises the following steps: reacting silybin with meglumine under optimized conditions to generate a liquid reactant, omitting a drying link, and directly adding the liquid reactant into an auxiliary material through spray gun atomization for one-step granulation; the auxiliary materials are screened and premixed, and after liquid reactants and the auxiliary materials are uniformly mixed, the temperature and spraying parameters are controlled to complete particle preparation. And after granulation, drying to a target water content by adopting fluidized bed drying equipment, and carrying out particle mixing, tabletting and coating to finally finish aluminum-plastic subpackaging and outer packaging. The process omits the traditional steps of drying, crushing and granulating, prevents reactants from being exposed to a high-temperature environment for a long time, and effectively improves the utilization rate of raw materials, the content of effective components and the purity of the product. Meanwhile, dust is reduced, the production environment is optimized, and the operation safety and the product yield are remarkably improved.

The invention belongs to the technical field of medicines, and particularly relates to a ketoprofen in-situ co-amorphous composition. The co-amorphous composition is prepared from ketoprofen, lysine, arginine and meglumine, and homogeneous disordered arrangement can be spontaneously formed when the co-amorphous composition is in contact with an aqueous medium (including a dissolution process). Through powder X-ray diffraction, differential scanning calorimetry and Fourier infrared spectroscopic analysis, the three combinations can be subjected to in-situ co-amorphization in contact with a trace aqueous medium or in a dissolution process, so that the solubility and the dissolution rate of ketoprofen are remarkably improved, and the oral absorption and treatment effects of ketoprofen are expected to be enhanced. Meanwhile, the degree of in-situ co-amorphization is closely related to composition molar ratio, contact time, medium pH and temperature. The invention provides a new preparation thought for mediating in-situ co-amorphous generation of ketoprofen through prescription composition and design and improving the defects of drug solubility and dissolution rate.

Salts of R-ketorolac, including solid salts, such as crystalline salts of the meglumine and tromethamine salts R-ketorolac, are disclosed. Methods of preparing such salts, pharmaceutical compositions comprising salts, and methods of treating cancer with such salts are further provided.

The invention provides a crystal form of a compound HIF-117 salt as well as a preparation method and application of the crystal form, and the crystal form is any one or more of the following crystal forms: a hydrochloride crystal form A, a sulfate crystal form B, a 1, 2-ethanedisulfonate crystal form C1, 1, 2-ethanedisulfonate crystal form C2, 1, 2-ethanedisulfonate crystal form C3 and 1, 2-ethanedisulfonate crystal form C4. The crystal form 1, 2-ethanedisulfonate crystal form C2, p-toluenesulfonate crystal form D, mesylate crystal form E1, mesylate crystal form E2, hydrobromide crystal form F1, hydrobromide crystal form F2, sodium salt crystal form G, sylvite crystal form H1, sylvite crystal form H2, calcium salt crystal form I, magnesium salt crystal form J, choline salt crystal form K, lysine salt crystal form L, ammonium salt crystal form M, meglumine salt crystal form N, betaine salt crystal form O1, betaine salt crystal form O2 and diethylamine salt crystal form P1, the invention relates to a diethylamine salt crystal form P1, a diethylamine salt crystal form P2, a diethylamine salt crystal form P3, a diethylamine salt crystal form P4, a diethylamine salt crystal form P5, a tromethamine salt crystal form Q1, a tromethamine salt crystal form Q2 and a tromethamine salt crystal form Q3. The compound has good stability, and has important value for development and production of medicines and preparations.

A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm / L.

The utility model relates to the field of medical product processing, in particular to concentration equipment for processing meglumine chlorzolate, which comprises a mounting rack, a concentration tank and a storage tank, the concentration tank is fixed on one side in the mounting rack, a plurality of filtering holes are arranged at the bottom in the concentration tank, and the storage tank is fixed on the other side in the mounting rack. A discharge hopper is arranged at the bottom of the concentration tank corresponding to the outside of the filter-out hole, an electric heating tube with a wiring end extending to the outside is mounted between the bottom in the discharge hopper and the outside of the concentration tank, and the discharge hopper and the bottom of the storage tank are both communicated with a discharge tube. The vacuum pump is used for creating a low-pressure environment, the boiling point of a solvent is reduced, low-temperature evaporation is realized, and the concentration efficiency is greatly improved; through a heating, stirring, condensing and pressure monitoring system which is accurately controlled by an electric heating tube, a motor, a bevel gear and a condenser, the stability of the whole concentration process is ensured, and the quality fluctuation is reduced; safety parts such as a check valve and a pressure gauge can improve safety of the system, and backflow and overpressure risks are prevented.

The invention discloses an ultra-long chain glucosamide nonionic surfactant and a synthesis method thereof. A hydrophobic tail chain of the surfactant is from plant-based fatty acid such as oleic acid, erucic acid or nervonic acid, and a hydrophilic head group is from glucose derivatives such as meglumine and glucamine. According to the method, oleic acid, erucic acid and nervonic acid in rapeseed byproducts are used as hydrophobic tail chain raw materials, glucose derivatives meglumine and glucamine are used as hydrophilic head group raw materials, methanol, ethanol, ethylene glycol or propylene glycol (a single solvent or a binary mixed solvent) is used as a solvent, DMAP or NaF is used as a catalyst, and the bio-based surfactant is obtained. The super-long-chain glucosamide nonionic surfactant is prepared through selective amination reaction, tedious protection on hydroxyl in glucosamine molecules is not needed, the reaction temperature is close to the room temperature, operation is easy and convenient, only a simple industrial crystallization method is needed in the purification process, and the method is suitable for industrial production.

The present invention provides a kind of favipiravir solution for atomized inhalation, preparation method and application. The inhalation solution contains 1-50mg / ml favipiravir, excipients and solvent in a single dose, and the pH value is 5.5-9.0, and the inhalation solution single dose specification is 2-5ml. The excipients include a cosolvent, a pH regulator and an osmotic pressure regulator. The cosolvent is selected from meglumine, and the mass ratio of favipiravir to meglumine is 1:1.25-1:1.34, and the pH regulator can be selected from sodium dihydrogen phosphate, disodium hydrogen phosphate, and one or more of potassium dihydrogen phosphate, the osmotic pressure regulator is selected from sodium chloride, and the solvent is selected from sterile water for injection. The solution of favipiravir can be used in combination with a liquid atomizer to provide a convenient, safe, effective and stable pharmaceutical dosage form and drug delivery system of favipiravir.

The present invention relates to new crystal salt forms of sulfasalazine, in particular crystal Form A of the D(-)-N-methylglucamine (meglumine) salt of sulfasalazine (see Figure 1), crystal form A of the piperazine salt of sulfasalazine (see Figure 2) and crystal Form B of the diethylamine salt of sulfasalazine (see Figure 4), which can be obtained by use of the inventive preparation process, a pharmaceutical composition comprising one or more of the inventive crystal salt forms in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and / or the gastro-intestinal tract.

The application discloses an arylpropionic acid non-steroidal anti-inflammatory drug preparation composition and a preparation method thereof. The composition is a solution preparation or a gel paste preparation containing arylpropionic acid non-steroidal anti-inflammatory drugs, and is characterized by containing arylpropionic acid non-steroidal anti-inflammatory drugs or isomers thereof and pharmaceutically acceptable solvents and adjuvants such as propylene glycol; wherein the mass / volume percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the solution preparation ranges from 1 mg / ml to 40 mg / ml, and the volume percentage of the propylene glycol ranges from 50% to 100%; the mass percentage of the arylpropionic acid non-steroidal anti-inflammatory drugs in the gel paste preparation ranges from 1% to 10%, and the mass percentage of the propylene glycol ranges from 5% to 12%. The arylpropionic acid non-steroidal anti-inflammatory drugs in the prescription are in RS-configuration or derivatives, R-configuration or derivatives, S-configuration or derivatives, or a combination of the R-configuration or derivatives and the S-configuration or derivatives in any ratio; and the pH regulator is one or more of lysine, arginine, tromethamine, meglumine and the like.

The invention belongs to the technical field of capsule preparations, and relates to a plant starch soft capsule and a preparation method thereof. The plant starch soft capsule is prepared from hydroxypropyl starch, carrageenan, plantain seed gum, sodium alginate, sodium hyaluronate and meglumine. The preparation method comprises the steps of raw material pretreatment, mixing and glue preparation, vacuum degassing, soft capsule forming and drying. Through the innovative raw material ratio and preparation process, the soft capsule has excellent weather resistance and can adapt to transportation and storage at extreme temperature; meanwhile, the product is mainly prepared from plant source raw materials, so that the fishy smell caused by gelatin is eliminated, and the use comfort and the market acceptability are improved. The plant starch soft capsule can be applied to the field of cosmetics and used as a carrier of active ingredients.

The present invention relates to a liquid pharmaceutical composition comprising (i) totally dissolved tretinoin or a pharmaceutically acceptable isomer thereof; (ii) d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS); (iii) a pH-modifying agent selected in the group consisting of meglumine, potassium hydroxide (KOH), sodium hydroxide (NaOH), sodium acetate (anhydrous, trihydrate, and mixtures thereof), potassium acetate (anhydrous, trihydrate, and mixtures thereof), di-potassium hydrogenophosphate, di-sodium hydrogenophosphate, tri-sodium phosphate, tri-potassium phosphate, and mixtures thereof; and (iv) water. The present invention also relates to the medical uses of such a composition.

The present invention relates to new crystal salt forms of sulfasalazine, in particular crystal Form A of the D(-)-N-methylglucamine (meglumine) salt of sulfasalazine (see Figure 1), crystal form A of the piperazine salt of sulfasalazine (see Figure 2) and crystal Form B of the diethylamine salt of sulfasalazine (see Figure 4), which can be obtained by use of the inventive preparation process, a pharmaceutical composition comprising one or more of the inventive crystal salt forms in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and / or the gastro-intestinal tract.

The application discloses a super-long chain glucose amide nonionic surfactant and a synthesis method thereof. The hydrophobic tail chain of the surfactant is derived from plant-based fatty acids such as oleic acid, erucic acid or nervonic acid, and the hydrophilic head group is derived from glucose derivatives such as meglumine and glycolglucamine. With oleic acid, erucic acid and nervonic acid in rapeseed by-product as hydrophobic tail chain raw material, glucose derivatives meglumine and glycolglucamine as hydrophilic head group raw material, methanol, ethanol, ethylene glycol or propylene glycol (single solvent or binary mixed solvent) as solvent, and DMAP or NaF as catalyst, a kind of bio-based surfactant is obtained. The super-long chain glucose amide nonionic surfactant is prepared by selective amination reaction, the hydroxyl group in the glucose amine molecule does not need to be protected complicatedly, the reaction temperature is close to room temperature, the operation is simple, and the purification process only needs a simple industrial crystallization method, which is suitable for industrial production.

The present disclosure provides meglumine salts of CX3CR1 modulators, polymorphs and pharmaceutical compositions thereof. Also disclosed are methods of treatment using the meglumine salts of CX3CR1 modulators, polymorphs and pharmaceutical compositions thereof and methods of making salt compounds of CX3CR1 modulators and polymorphs thereof.